Bob is currently the Executive Chairman and CEO of Imagion Biosystems, a company developing a new functional imaging technology for the early detection of cancer. In 2017 Bob led the company through a spinout restructuring which included an IPO on the Australian Securities Exchange. Bob has more than 25 years of experience in product development and commercialization in the computer, life science, and medical diagnostics industries. Previous employment includes Pres/GM for Silicon Biosystems, where he established the commercial introduction of a new image-based liquid biopsy diagnostic technology, and Vice President Marketing and Sales for Nanogen with a DNA chip-based diagnostic technology. Mr. Proulx holds an M.A. and B.A. from The State University of New York at Albany and an Executive MBA from the Penn State Smeal College of Business.